HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -- 48-week trial will enroll approximately 150 ...
Dyne Therapeutics has initiated the Phase III HARMONIA trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (z-basivarsen, also called DYNE-101) in individuals diagnosed ...
Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...
The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop ...
The timing of the partial hold is “odd,” according to analysts at Stifel, who noted that the preclinical data the FDA took ...
Comedian Gilbert Gottfried, shown in a 2016 photo, died on Tuesday, April 12, from recurrent ventricular tachycardia due to myotonic dystrophy type II. Scott Roth Scott Roth/Invision/AP Comedian ...
Myotonic dystrophy is a hereditary degenerative neuromuscular disease that occurs mainly in adults, affecting about 50,000 people only in Spain. Symptoms range from difficulty walking and myotonia ...
DUBLIN--(BUSINESS WIRE)--The "Myotonic Dystrophy - Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.com's offering. The "Myotonic Dystrophy - Pipeline Insight, 2023" report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results